Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 20, 2018

View Archived Issues

EZH2 as a novel therapeutic target for restoration of MHC expression in DLBCL

BPX-601 well tolerated in first-in-human study in advanced solid tumors

LB-100 shows preclinical efficacy against lapatinib-resistant HER2-positive breast cancer models

BiTE expression by oncolytic virus for targeted killing of cancer cells and associated fibroblasts

Spheroid-based xenograft model better mimics pancreatic ductile adenocarcinoma

HAL Allergy begins first-in-human study of HAL-MRE1 in ragweed allergic patients

Lilly begins phase III study of tirzepatide in patients with type 2 diabetes and cardiovascular risk

Less is more for durable STING effects

Bacterial toxins weaken gut barrier

Dexmedetomidine can be used to treat agitation without affecting blood pressure or heart rate

Sabutoclax as potential new strategy for patients with chemoresistant breast cancer

PsychENCODE casts light on genetics of psychiatric diseases

Silence Therapeutics adds LP(a)-targeting siRNA medicine SLN-360 to preclinical pipeline

Araxes Pharma presents mutant RAS inhibitors

BCL2 coding mutation is associated with venetoclax resistance in CLL

Enanta Pharmaceuticals discloses MAP3K5 inhibitors

U.S. researchers identify new antibacterial compounds

Suzhou Autopharm Biopharmaceutical synthesizes MAP1LC3B inhibitors

Kyn Therapeutics initiates two phase Ib/II trials of ARY-007 in collaboration with Merck & Co.

Phase I results reported for CAR T-cell therapy targeting both CD19 and CD22 in ALL

Southern Research Institute describes new LRRK2 inhibitors

AzurRx BioPharma initiates phase II OPTION study of MS1819-SD

Gilead and Scholar Rock enter collaboration to develop novel therapies for fibrotic diseases

Medigene reports interim data from phase I/II study of DC vaccine in AML

G1's phase II study of trilaciclib with topotecan in second-/third-line SCLC meets primary endpoints

Keytruda gets FDA approval for recurrent locally advanced or metastatic Merkel cell carcinoma

FDA approves Lynparza for first-line maintenance therapy in BRCA-mutated advanced ovarian cancer

FDA approves Envarsus XR to prevent organ rejection in de novo kidney transplant patients

Toripalimab first domestically produced anti-PD-1 MAb approved in China

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...